Research ArticleArticle
Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study
Amir M. Mohareb, Naomi J. Patel, Xiaoqing Fu, Arthur Y. Kim, Zachary S. Wallace and Emily P. Hyle
The Journal of Rheumatology August 2021, jrheum.210257; DOI: https://doi.org/10.3899/jrheum.210257
Amir M. Mohareb
AMM is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; T32AI007433). NJP is supported by the NIH (T32AR007258). AYK is supported by NIH/ NIAID [AI082630]. EPH is supported by the NIH/National Heart, Lung, and Blood Institute (K01HL123349). ZSW is funded by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR073334 and L30 AR070520). The NIH had no role in the design or authorship of this publication. The article contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School; N.J. Patel, MD, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; X. Fu, MS, Z.S. Wallace, MD, MSc, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital; A.Y. Kim, MD, Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A.M. Mohareb, 16th Floor, Medical Practice Evaluation Center, 100 Cambridge Street, Boston, MA 02114, USA. Email: amohareb@mgh.harvard.edu. Accepted for publication July 16, 2021.
Naomi J. Patel
AMM is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; T32AI007433). NJP is supported by the NIH (T32AR007258). AYK is supported by NIH/ NIAID [AI082630]. EPH is supported by the NIH/National Heart, Lung, and Blood Institute (K01HL123349). ZSW is funded by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR073334 and L30 AR070520). The NIH had no role in the design or authorship of this publication. The article contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School; N.J. Patel, MD, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; X. Fu, MS, Z.S. Wallace, MD, MSc, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital; A.Y. Kim, MD, Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A.M. Mohareb, 16th Floor, Medical Practice Evaluation Center, 100 Cambridge Street, Boston, MA 02114, USA. Email: amohareb@mgh.harvard.edu. Accepted for publication July 16, 2021.
Xiaoqing Fu
AMM is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; T32AI007433). NJP is supported by the NIH (T32AR007258). AYK is supported by NIH/ NIAID [AI082630]. EPH is supported by the NIH/National Heart, Lung, and Blood Institute (K01HL123349). ZSW is funded by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR073334 and L30 AR070520). The NIH had no role in the design or authorship of this publication. The article contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School; N.J. Patel, MD, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; X. Fu, MS, Z.S. Wallace, MD, MSc, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital; A.Y. Kim, MD, Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A.M. Mohareb, 16th Floor, Medical Practice Evaluation Center, 100 Cambridge Street, Boston, MA 02114, USA. Email: amohareb@mgh.harvard.edu. Accepted for publication July 16, 2021.
Arthur Y. Kim
AMM is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; T32AI007433). NJP is supported by the NIH (T32AR007258). AYK is supported by NIH/ NIAID [AI082630]. EPH is supported by the NIH/National Heart, Lung, and Blood Institute (K01HL123349). ZSW is funded by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR073334 and L30 AR070520). The NIH had no role in the design or authorship of this publication. The article contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School; N.J. Patel, MD, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; X. Fu, MS, Z.S. Wallace, MD, MSc, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital; A.Y. Kim, MD, Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A.M. Mohareb, 16th Floor, Medical Practice Evaluation Center, 100 Cambridge Street, Boston, MA 02114, USA. Email: amohareb@mgh.harvard.edu. Accepted for publication July 16, 2021.
Zachary S. Wallace
AMM is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; T32AI007433). NJP is supported by the NIH (T32AR007258). AYK is supported by NIH/ NIAID [AI082630]. EPH is supported by the NIH/National Heart, Lung, and Blood Institute (K01HL123349). ZSW is funded by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR073334 and L30 AR070520). The NIH had no role in the design or authorship of this publication. The article contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School; N.J. Patel, MD, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; X. Fu, MS, Z.S. Wallace, MD, MSc, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital; A.Y. Kim, MD, Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A.M. Mohareb, 16th Floor, Medical Practice Evaluation Center, 100 Cambridge Street, Boston, MA 02114, USA. Email: amohareb@mgh.harvard.edu. Accepted for publication July 16, 2021.
Emily P. Hyle
AMM is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; T32AI007433). NJP is supported by the NIH (T32AR007258). AYK is supported by NIH/ NIAID [AI082630]. EPH is supported by the NIH/National Heart, Lung, and Blood Institute (K01HL123349). ZSW is funded by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR073334 and L30 AR070520). The NIH had no role in the design or authorship of this publication. The article contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School; N.J. Patel, MD, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital; X. Fu, MS, Z.S. Wallace, MD, MSc, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital; A.Y. Kim, MD, Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A.M. Mohareb, 16th Floor, Medical Practice Evaluation Center, 100 Cambridge Street, Boston, MA 02114, USA. Email: amohareb@mgh.harvard.edu. Accepted for publication July 16, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study
Amir M. Mohareb, Naomi J. Patel, Xiaoqing Fu, Arthur Y. Kim, Zachary S. Wallace, Emily P. Hyle
The Journal of Rheumatology Aug 2021, jrheum.210257; DOI: 10.3899/jrheum.210257
Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study
Amir M. Mohareb, Naomi J. Patel, Xiaoqing Fu, Arthur Y. Kim, Zachary S. Wallace, Emily P. Hyle
The Journal of Rheumatology Aug 2021, jrheum.210257; DOI: 10.3899/jrheum.210257